From the global outbreak of SARSCoV caused infection disease in 2003, coronaviruses (CoVs) are known to be a great threat to the human health. Recently, a new SARS-like coronavirus, human betacoronavirus 2c EMC/2012 (HCoV-EMC), has been identified and the appearance of this new CoV raises concerns that a new spread of CoV may occurs in the future. By solving the crystal structure of HCoV-EMC main protease with a wide-spectrum anti-CoV inhibitor N3, we confi rmed that that N3 blocks the function of HCoV-EMC main protease through a similar mechanism to other CoVs. Together with the good pharmaceutical features, N3 is conceivable to be effective to HCoV-EMC and other CoVs appearing in the future. These fi ndings make it convincing that CoVs will not be a threat to human health.
In the year of 2012, a new respiratory illness similar to severe acute respiratory syndrome (SARS) that spread globally in 2003 and infected over 8,000 people with more than 800 fatalities (Li et al., 2010) , was identifi ed in Europe, the Middle East and Hong Kong. The infection was reported to manifest clinically with fever, cough and breathing diffi culties. Some patients also developed acute renal failure. Sequence analysis suggested that the causative agent of this newly emerged SARS-like illness is a new coronavirus (CoV) which has been named as the human betacoronavirus 2c EMC/2012 (HCoV-EMC) . No clinically approved treatment is available for CoV infection since the outbreak of SARS in 2003, the appearance of this new CoV raises concerns that a new epidemic of CoV infection may occur in future.
CoVs are positive-sense, singlestranded RNA viruses and are featured by the largest viral RNA genomes known to date (Yang et al., 2003) . Replication of coronavirus requires correct proteolytic processing of the replicase polyprotein by viral proteases, in particular a chymotrypsin-like protease (3CL pro , also known as main protease M pro ).
Since 3CL pro is unique in the virus but not found in the host cell, this protein is a prominent target for the development antivirals against CoV infections (Yang et al., 2005) , and a number of inhibitors have been discovered that prohibit the infection of CoV through their action on 3CL pro (Yang et al., 2005) .
To elucidate the inhibitory mechanism and provide information to aid the discovery of new candidate compounds against CoV infections, we present the crystal structure of HCoV-EMC 3CL pro complexed with the broad-spectrum anti-CoV inhibitor N3. HCoV-EMC 3CL pro processes a conserved molecular fold and the dimeric architecture of CoV main proteases (Fig. 1A) , which is consistent with that was observed in SARS-CoV 3CL pro (Yang et al., 2003) .
A protomer of HCoV-EMC 3CL pro dimer is featured by three domains: Domains I (residues Ser1-Pro102) and II (residues Ala103-Asp200) process an antiparalleled β-barrel structure and shares high structural similarity with trypsin-like serine proteases. Domain III (residues Lys201-Gln306) contains fi ve α-helices to form a compact globular structure. The catalytic dyad Cys148-His41 and the substrate binding site of pro are located on the interface of Domain I and II, which is identified by the bound inhibitor N3 (Fig. 1B) (Liang, 2006; Lee et al., 2009) . Although the inhibitory effect of inhibitor N3 to HCoV-EMC 3CL pro is not extremely good, it presents good pharmaceutical properties with comparable inhibitory activity (Fig. S2) . The β-phase half-life (t 1/2 ) of inhibitor N3 was 70 min and all rats survive with the injection of 140 mg/kg N3. These results indicate the great potential to make inhibitor N3 as the wide-spectrum anti-CoV drug in the future.
Besides HCoV-EMC, a number of coronaviruses, e.g. alphacoronavirus HKL10, have been isolated from bat (Lau et al., 2012) . Although these newly identifi ed CoVs display distinct epidemic and pathologic features, they present high sequence and structure similarity for virally encoded proteins, in particular the replicase protein, with those of SARS-CoV and other well-known CoVs. It is conceivable that current inhibitors, which were discovered based on SARS-CoV, are also effective against HCoV-EMC and other CoVs that may appear in future. If this "Achilles' heel" hypothesis proves to be correct, CoVs will not be a threat to human health.
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